Lipigon Pharmaceuticals (Sweden) Performance
| LPGO Stock | SEK 0.19 0.01 5.00% |
The company secures a Beta (Market Risk) of -0.21, which conveys not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Lipigon Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Lipigon Pharmaceuticals is likely to outperform the market. At this point, Lipigon Pharmaceuticals has a negative expected return of -0.15%. Please make sure to verify Lipigon Pharmaceuticals' total risk alpha, potential upside, kurtosis, as well as the relationship between the treynor ratio and skewness , to decide if Lipigon Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Lipigon Pharmaceuticals AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
| Begin Period Cash Flow | 12.6 M | |
| Total Cashflows From Investing Activities | -119 K |
Lipigon |
Lipigon Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 25.00 in Lipigon Pharmaceuticals AB on September 13, 2024 and sell it today you would lose (6.00) from holding Lipigon Pharmaceuticals AB or give up 24.0% of portfolio value over 90 days. Lipigon Pharmaceuticals AB is generating negative expected returns and assumes 7.692% volatility on return distribution over the 90 days horizon. Simply put, 68% of stocks are less volatile than Lipigon, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Lipigon Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lipigon Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lipigon Pharmaceuticals AB, and traders can use it to determine the average amount a Lipigon Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0201
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | LPGO |
Estimated Market Risk
| 7.69 actual daily | 68 68% of assets are less volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.02 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Lipigon Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lipigon Pharmaceuticals by adding Lipigon Pharmaceuticals to a well-diversified portfolio.
Lipigon Pharmaceuticals Fundamentals Growth
Lipigon Stock prices reflect investors' perceptions of the future prospects and financial health of Lipigon Pharmaceuticals, and Lipigon Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lipigon Stock performance.
| Return On Equity | -1.7 | |||
| Return On Asset | -0.94 | |||
| Operating Margin | (338.33) % | |||
| Current Valuation | 5.58 M | |||
| Shares Outstanding | 20.24 M | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 147.83 X | |||
| Revenue | 3.18 M | |||
| EBITDA | (41.09 M) | |||
| Cash And Equivalents | 58.95 M | |||
| Cash Per Share | 6.06 X | |||
| Book Value Per Share | 0.65 X | |||
| Cash Flow From Operations | (35.3 M) | |||
| Earnings Per Share | (4.65) X | |||
| Total Asset | 29.43 M | |||
About Lipigon Pharmaceuticals Performance
Assessing Lipigon Pharmaceuticals' fundamental ratios provides investors with valuable insights into Lipigon Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Lipigon Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Lipigon Pharmaceuticals AB develops drugs for lipid related diseases in Sweden. Lipigon Pharmaceuticals AB was founded in 2010 and is based in Ume, Sweden. Lipigon Pharmaceuticals is traded on Stockholm Stock Exchange in Sweden.Things to note about Lipigon Pharmaceuticals performance evaluation
Checking the ongoing alerts about Lipigon Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lipigon Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lipigon Pharmaceuticals generated a negative expected return over the last 90 days | |
| Lipigon Pharmaceuticals has high historical volatility and very poor performance | |
| Lipigon Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Lipigon Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 3.18 M. Net Loss for the year was (41.11 M) with loss before overhead, payroll, taxes, and interest of (36.04 M). | |
| Lipigon Pharmaceuticals AB has accumulated about 58.95 M in cash with (35.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.06, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 38.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Lipigon Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lipigon Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Lipigon Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lipigon Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lipigon Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lipigon Pharmaceuticals' stock. These opinions can provide insight into Lipigon Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Lipigon Stock Analysis
When running Lipigon Pharmaceuticals' price analysis, check to measure Lipigon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipigon Pharmaceuticals is operating at the current time. Most of Lipigon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lipigon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipigon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lipigon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.